BFH772 (VEGFR2 inhibitor): Technical Guidance and Best Practices

What This Product Solves

BFH772 (CAS 890128-81-1) is a potent small-molecule VEGFR2 kinase inhibitor designed for targeted inhibition of the VEGFR2 signaling pathway. VEGFR2 is a critical receptor tyrosine kinase activated by VEGF family ligands (VEGF-A, VEGF-B, VEGF-C, VEGF-D) and placental growth factor (PlGF), and is central to angiogenesis processes, particularly in pathological tumor environments. With an IC50 value of 3 nM for VEGFR2 and a high selectivity profile (approximately 500-fold lower potency for related receptors FLK-1, FLT-1, FLT-4, and 40-fold less efficacy for off-target kinases), BFH772 provides a research tool for dissecting VEGFR2-driven angiogenic mechanisms. This makes it suitable for studies of tumor angiogenesis, evaluation of anti-angiogenic agents, and preclinical assessment of VEGFR2 pathway modulation, particularly where precise kinase selectivity is required. For more details and up-to-date product specifications, see the BFH772 (VEGFR2 inhibitor) product page.

Protocol Parameters

• Solvent Compatibility: DMSO (≥53.4 mg/mL), Ethanol (≥15.33 mg/mL) | applicability: Required for stock preparation | rationale: BFH772 is insoluble in water and must be dissolved in organic solvents for use in in vitro and in vivo assays | source_type: product dossier
• Storage Temperature: -20°C (powder) | applicability: Long-term preservation of compound integrity | rationale: Maintains stability and potency; avoid repeated freeze-thaw cycles | source_type: product dossier
• Purity Requirement: ≥96% (QC-verified) | applicability: Reproducible experimental outcomes | rationale: High-purity material reduces confounding by impurities in kinase inhibition studies | source_type: product dossier
• Working Solution Stability: Prepare fresh; avoid long-term storage in solution | applicability: Ensures consistent activity in assays | rationale: Solution stability is limited; degradation may occur with prolonged storage even at low temperatures | source_type: product dossier
• Recommended Vehicle Controls: Use equivalent DMSO or ethanol concentrations in controls | applicability: Validates specificity in cell-based and animal assays | rationale: Controls for solvent-related effects on cells or tissues | source_type: workflow recommendation

Workflow Setup and QC Checklist

Compound Preparation: Dissolve BFH772 in DMSO or ethanol to make a concentrated stock (e.g., 10–20 mM), ensuring complete dissolution with gentle vortexing or brief sonication. Avoid water as a solvent due to insolubility. Filter sterilize if needed for cell-based applications. Prepare aliquots for single-use to minimize freeze-thaw cycles and potential compound degradation.

Assay Design: When planning VEGFR2 signaling pathway inhibitor assays or tumor angiogenesis research, select BFH772 concentrations relative to the IC50 (3 nM for VEGFR2) and the specific cell or animal model's sensitivity. Include both positive and negative controls, and use vehicle controls matched for DMSO or ethanol concentration.

Quality Control (QC): Verify batch purity via the provided certificate of analysis (≥96%). Confirm solubility visually—solutions should be clear, with no precipitate. Document lot number, preparation date, and storage conditions for traceability. For best practice, reference the Technical Workflow and QC Guidance, which provides additional insight into workflow setup and reproducibility.

Common Failure Modes and Fixes

• Precipitation or Cloudiness in Solution: If BFH772 does not fully dissolve, ensure solvent is DMSO or ethanol and increase agitation or mild heating (avoid high heat). Filter if needed. Always verify concentration remains within solubility parameters.
• Unexpected Loss of Activity: Decreased inhibition may result from repeated freeze-thaw cycles or prolonged storage of working solutions. Always prepare fresh working solutions and store powder at -20°C. Discard solutions after each use.
• Non-specific Effects in Controls: If off-target or solvent-related cytotoxicity is observed, verify vehicle control concentrations match those in treated groups. Reduce DMSO or ethanol percentages where possible and confirm cell/animal model tolerance.
• Variability Between Batches: Always confirm batch purity and document handling. Use QC-verified lots and retain certificates of analysis for reference.

Scope and Limitations

BFH772 is optimized as a selective VEGFR2 kinase inhibitor for angiogenesis research, particularly in tumor model systems. Its high selectivity profile makes it unsuitable for studies requiring broad-spectrum kinase inhibition or for protocols needing water-soluble compounds. Limitations include:

• Not suitable for aqueous-based protocols or those requiring high compound concentrations in water.
• Should not be used for inhibition of kinases outside the VEGFR2 family due to markedly reduced potency for FLK-1, FLT-1, FLT-4, B-RAF, RET, and TIE-2.
• Degradation risk with storage of solutions; always use freshly prepared aliquots.

For more practical application guidelines, see the Technical Guide for Angiogenesis Research, which discusses BFH772's selectivity and workflow compatibility in greater detail.

Conclusion

BFH772 (VEGFR2 inhibitor) presents a technically robust option for precise modulation of VEGFR2-driven angiogenesis, especially in tumor angiogenesis research settings where selectivity and solvent compatibility are critical. Adherence to recommended preparation, storage, and QC practices is essential for reproducible results. For comprehensive technical data and ordering information, refer to the BFH772 (VEGFR2 inhibitor) product page from APExBIO.